Prediction of Human Pharmacokinetic Parameters Using Animal Data and Principles of Allometry

Nuggehally R. Srinivas; Preeti Ahlawat

doi:10.1055/s-0031-1296450

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2009; 59(12): 625-630
DOI: 10.1055/s-0031-1296450

Reviews

Editio Cantor Verlag Aulendorf (Germany)

Prediction of Human Pharmacokinetic Parameters Using Animal Data and Principles of Allometry

A case using bicifadine, a non-narcotic analgesic, as an example

Nuggehally R. Srinivas

¹Integrated Drug Development, Suramus Biopharm, Bangalore, (India)

,

Preeti Ahlawat

²Clintec International (India) Pvt Ltd, Koramangala, Bangalore, (India)

› Author Affiliations

Abstract

Allometry scaling of preclinical pharmacokinetic parameters for bicifadine (CAS 71195-57-8), a novel non-narcotic analgesic, was performed to predict the human pharmacokinetic parameters of clearance (CL_iv and CL_oral) and volume of distribution (V_z). The metabolism pattern, biotransformation pathways, and the predominant urinary excretion of the formed metabolites of bicifadine were found to be similar amongst mice, rats, monkeys and humans facilitating the scaling process. The availability of gender specific data in the preclinical species rendered the prediction of bicifadine parameters in gender specific groups. The human parameters for CL_iv,V_z, and CL_oral were predicted by allometric equations: 1.5252W^0.742 (R² = 0.9989), 1.3489W^0.8484 (R² = 0.9896), 3.2516W^0.7694 (R² = 0.9875), respectively. The absolute bioavailability for bicifadine was estimated to be approximately 67%. The predicted CL_oral (95 L/h) was within 45% of the human reported value (59 L/h). Overall, based on the closeness of allometric exponents (within 15% of suggested values), simple allometry approach could be used to prospectively predict the human pharmacokinetic parameters of bicifadine with confidence.

Key words

Allometiy - Bicafadine, clearance, pharmacokinetics, volume of distribution - CAS 71195-57-8 - Non-narcotic analgesic

Full Text

References

Literature
1 Epstein JW, Osterberg AC, Regan BA. Bicifadine: nonnarcotic analgesic activity of 1-aryl-3-azabicyclo[3.1.0]hexanes. NIDA Res Monogr. 1982; 41: 93-8
2 Basile AS, Janowsky A, Golembiowska K, Kowalska M, Nowak G, Benveniste M et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent and chronic pain. J Pharmacol Exp Ther. 2008; 321: 1208-25
3 Stern W, Czobor P, Stark J, Krieter P. Relationship between plasma bicifadine levels and analgesic effect in a dental pain model. Proceedings of the 11th World Congress on Pain; 2005 Aug 21–26; Sydney, Australia. Seattle: International Association for the Study of Pain;
4 Riff D, Huang N, Czobor P, Stern W. A five-day, multi-center, randomized, placebo-controlled, double blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of post operative bunionectomy pain. J Pain. 2005; 7 (Suppl 2) S40
5 Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA. Pharmacokinetics, Disposition, and Metabolism of Bicifadine in the Mouse, Rat, and Monkey. Drug Metab Dispos. 2007; 36: 241-51
6 Krieter PA, Gohdes M, Musick TJ, Duncanson FP, Bridson WE. Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans. Drug Metab Dispos. 2007; 36: 252-9
7 Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev. 2007; 59: 1177-92
8 Mahmood I, Martinez M, Hunter RP. Interspecies allometric scaling. Part I: prediction of clearance in large animals. J Vet Pharmacol Ther. 2006; 29: 415-23
9 Ahlawat P, Srinivas NR. Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data. Xenobiotica. 2008; 38: 1377-85
10 Ahlawat P, Srinivas NR. Allometric predictions for the human pharmacokinetic parameters for naveglitazar. Eur J Drug Metab Pharmacokin. 2008; 33: 187-90
11 Bhamidipati RK, Dravid PV, Mullangi R, Srinivas NR. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica. 2004; 34: 571-9
12 Lave T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta MA et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol. 1999; 51: 85-91
13 Pavankumar VV, Vinu CA, Mullangi R, Srinivas NR. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur J Drug Metab Pharmacokin. 2007; 32: 29-37
14 Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol. 2001; 53: 1629-39
15 Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos. 1999; 27: 1232-41
16 Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci. 2004; 93: 2522-34
17 Tang H, Mayersohn M. A Mathematical Description of the Functionality of Correction Factors Used in Allometry for Predicting Human Drug Clearance. Drug Metab Dispos. 2005; 33: 1294-6
18 Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007; 35: 2232-41
19 Ong CK, Lirk P, Tan JM, Sow BW. The analgesic efficacy of intravenous versus oral tramadol for preventing postoperative pain after third molar surgery. J Oral Maxillofac Surg. 2005; 36: 1162-8
20 Hu T-M, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainity versus universality. AAPS PharmSci. 2001; 3 (4) E29
21 Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs. allometric scaling. Xenobiotica. 2006; 36: 567-80
22 Mahmood I. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling: A comparative study of two approaches. Drug Metabol Drug Interact. 2002; 19: 49-64
23 Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos. 2005; 33: 1288-93
24 Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H et al. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 2009; 49 (5) 513-33
25 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10: 1093-5